ROSALINE Trial for Patients with Early-Stage Lobular Breast Cancer
The combination of Letrozole and Entrectinib is being evaluated as an effective therapy for inhibiting invasive lobular carcinoma tumor growth in early‑stage breast cancer patients.
This trial will test whether the new combination of two approved drugs will be an effective therapy for inhibiting lobular breast cancer tumor growth.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC